Skip to main content

Mantle Cell Lymphoma News

News
04/10/2025
Danielle Sposato
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study published in Scientific Reports involving 979 patients from 9 cancer centers has introduced a powerful new prognostic tool for mantle cell lymphoma (MCL), a rare and aggressive form of non-Hodgkin lymphoma.
A large retrospective study...
04/10/2025
Journal of Clinical Pathways
News
04/07/2025
Hannah Musick
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients found significant survival gains linked to increased first-line use of rituximab-bendamustine (BR) and Bruton tyrosine kinase inhibitors (BTKis), but more modest improvements after second-line therapy.
A study of older MCL patients...
04/07/2025
Journal of Clinical Pathways
News
03/18/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell lymphoma (MCL) who receive treatment at academic cancer centers experience longer overall survival and higher participation in clinical trials compared to those treated in community-based practices, according to a...
Patients with mantle cell...
03/18/2025
Journal of Clinical Pathways
News
03/12/2025
Lisa Kuhns, PhD, MD
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell lymphoma (MCL) can benefit from measurable residual disease (MRD) assessment during induction therapy, with the timing and kinetics of MRD negativity significantly impacting prognosis and treatment strategies,...
Patients with mantle cell...
03/12/2025
Journal of Clinical Pathways
News
03/04/2025
Juliet Gallagher
A real-world study comparing treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) found that chimeric antigen receptor T-cell (CAR T) therapy was associated with...
A real-world study comparing treatment patterns, health care resource utilization, and costs in patients with relapsed/refractory mantle cell lymphoma (R/R MCL) found that chimeric antigen receptor T-cell (CAR T) therapy was associated with...
A real-world study comparing...
03/04/2025
Journal of Clinical Pathways
News
02/21/2025
Lisa Kuhns, PhD, MD
Higher Cyclin D1 protein levels detected through a novel quantification method correlate with better survival outcomes in patients with mantle cell lymphoma (MCL), highlighting its prognostic ability, according to a study published in...
Higher Cyclin D1 protein levels detected through a novel quantification method correlate with better survival outcomes in patients with mantle cell lymphoma (MCL), highlighting its prognostic ability, according to a study published in...
Higher Cyclin D1 protein levels...
02/21/2025
Journal of Clinical Pathways
News
02/12/2025
Lisa Kuhns, PhD, MD
Consolidative autologous hematopoietic cell transplant (auto-HCT) provides no additional benefit for patients with mantle cell lymphoma (MCL) achieving undetectable minimal residual disease (uMRD6) in their first complete remission (CR),...
Consolidative autologous hematopoietic cell transplant (auto-HCT) provides no additional benefit for patients with mantle cell lymphoma (MCL) achieving undetectable minimal residual disease (uMRD6) in their first complete remission (CR),...
Consolidative autologous...
02/12/2025
Journal of Clinical Pathways
News
02/03/2025
Juliet Gallagher
A study published in Blood Advances demonstrated that PIK3CA gains and PTEN losses in mantle cell lymphoma drive therapeutic resistance, metabolic reprogramming, and reduced dependence on B-cell receptor signaling, highlighting the need for...
A study published in Blood Advances demonstrated that PIK3CA gains and PTEN losses in mantle cell lymphoma drive therapeutic resistance, metabolic reprogramming, and reduced dependence on B-cell receptor signaling, highlighting the need for...
A study published in Blood...
02/03/2025
Journal of Clinical Pathways
News
02/14/2024
Grace Taylor, MS, MA
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated...
02/14/2024
Journal of Clinical Pathways
Conference Coverage
12/10/2022
Katie Herman
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and...
12/10/2022
Journal of Clinical Pathways